← Eichor
Study identifier: NCT07717372 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

The C-reactive Protein (CRP) Point of Care Testing (POCT) Implementation to Adult Patients Presenting With Symptoms of the Acute Respiratory Tract Infection (ARTI) in Eight Primary Health Care (PHC) in Jakarta.

Condition: Adults · Acute Respiratory Tract Infection · Antibiotic Prescriptions  ·  Sponsor: Oxford University Clinical Research Unit Indonesia

PhaseNA
Planned participants2544
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersYes

About this study

Antimicrobial resistance (AMR) has emerged as one of the most pressing global health challenges of the 21st century, particularly Indonesia is projected to be among the five nations globally with the highest percentage increase in antimicrobial consumption by 2030. Primary care settings represent the most critical implementation point for addressing inappropriate antibiotic use. ARTI constitutes the most common indication for antibiotic prescribing in primary care, yet much of this prescribing is inappropriate. The high frequency of inappropriate antibiotic prescribing for ARTI is particularly problematic because most of these infections are viral in nature and resolve spontaneously without antibiotic treatment. Studies across the Asia-Pacific region, including Indonesia, have documented antibiotic prescribing rates for upper respiratory tract infections ranging from 47% to 85%, indicating substantial overuse. C-reactive protein (CRP) point-of-care test (POCT) has emerged as a promising, evidence-based implementation to reduce inappropriate antibiotic prescribing for acute respiratory infections in a systematic review of studies conducted primarily in primary care settings of high- and middle-income countries. However, the efficacy and safety of CRP POCT implementation have not been evaluated in Indonesian primary care settings, where healthcare infrastructure, patient populations, test acceptability, and prescribing practices may differ significantly from countries where st…

This description comes directly from the study's public registry record.

Talk to the study team

Robert Sinto, MD, DPhil  ·  +622123599099  ·  rsinto@oucru.org

Raph L Hamers, MD, PhD  ·  +622123599099  ·  rhamers@oucru.org

Always discuss trial participation with your own doctor first.

Locations (8)

Cengkareng Public Health CenterJakarta, IndonesiaRecruiting
Kebayoran Lama Public Health CenterJakarta, IndonesiaEnrolling By Invitation
Pulo Gadung Public Health CenterJakarta, IndonesiaRecruiting
Jatinegara Public Health CenterJakarta, IndonesiaRecruiting
Duren Sawit Public Health CenterJakarta, IndonesiaRecruiting
Cakung Public Health CenterJakarta, IndonesiaRecruiting
Cilincing Public Health CenterJakarta, IndonesiaRecruiting
Koja Public Health CenterJakarta, IndonesiaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07717372